Evidence map›Paper›PMID 16800721›Full record

ArticlePLoS medicine2006

Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development.

Hongye Liu, Alvin T Kho, Isaac S Kohane, Yao Sun

Abstract readComparative Study
In one paragraph

Article in PLoS medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Small cell lung cancer: will recent progress lead to improved outcomes?Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hongye LiuChildren's Hospital Informatics Program, Children's Hospital Boston, Boston, Massachusetts, United States of America. hongye.liu@childrens.harvard.edu
Alvin T Kho
Isaac S Kohane
Yao Sun

Funding

Informatics for Integrating Biology/ the Bedside (RMI)U54LM008748 · NLM · BRIGHAM AND WOMEN'S HOSPITAL · PI KOHANE, ISAAC S. · 2004 to 2013
$39.0M
Transcriptional control of inhibitory synapse formationP01NS047572 · NINDS · DANA-FARBER CANCER INSTITUTE · PI GREENBERG, MICHAEL ELDON · 2004 to 2013
$13.5M
Progenitor Cells inHuman Skeletal MuscleP01NS040828 · NINDS · CHILDREN'S HOSPITAL BOSTON · PI GUSSONI, EMANUELA · 2001 to 2007
$8.6M
Mechanisms of hedge-hog induced neuroproliferationR01NS047527 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROWITCH, DAVID H · 2004 to 2007
$1.4M
NINDS NIH HHS P01 NS040828NINDS NIH HHS P01 NS047572NINDS NIH HHS P01 NS047572-01ANINDS NIH HHS P01 NS40828NINDS NIH HHS R01 NS047527NLM NIH HHS 5U54LM008748-02NLM NIH HHS U54 LM008748
6 · The paper itself

Abstract

backgroundThe histopathologic heterogeneity of lung cancer remains a significant confounding factor in its diagnosis and prognosis-spurring numerous recent efforts to find a molecular classification of the disease that has clinical relevance. METHODS AND

findingsMolecular profiles of tumors from 186 patients representing four different lung cancer subtypes (and 17 normal lung tissue samples) were compared with a mouse lung development model using principal component analysis in both temporal and genomic domains. An algorithm for the classification of lung cancers using a multi-scale developmental framework was developed. Kaplan-Meier survival analysis was conducted for lung adenocarcinoma patient subgroups identified via their developmental association. We found multi-scale genomic similarities between four human lung cancer subtypes and the developing mouse lung that are prognostically meaningful. Significant association was observed between the localization of human lung cancer cases along the principal mouse lung development trajectory and the corresponding patient survival rate at three distinct levels of classical histopathologic resolution: among different lung cancer subtypes, among patients within the adenocarcinoma subtype, and within the stage I adenocarcinoma subclass. The earlier the genomic association between a human tumor profile and the mouse lung development sequence, the poorer the patient's prognosis. Furthermore, decomposing this principal lung development trajectory identified a gene set that was significantly enriched for pyrimidine metabolism and cell-adhesion functions specific to lung development and oncogenesis.

conclusionsFrom a multi-scale disease modeling perspective, the molecular dynamics of murine lung development provide an effective framework that is not only data driven but also informed by the biology of development for elucidating the mechanisms of human lung cancer biology and its clinical outcome.

Indexed as

Gene Expression Regulation, DevelopmentalGene Expression Regulation, NeoplasticAdenocarcinomaAlgorithmsAnimalsCarcinoid TumorCarcinoma, Non-Small-Cell LungCarcinoma, Small CellCell AdhesionCell Transformation, NeoplasticGene Expression ProfilingGenes, cdcGenomicsHumansKaplan-Meier EstimateLungPyrimidinesRNA, MessengerRNA, Neoplasm

Identifiers

PMID16800721
PMCPMC1483910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.